Welcome to our dedicated page for Esperion Therapeutics SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Esperion Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Esperion Therapeutics's regulatory disclosures and financial reporting.
Sheldon Koenig filed a Form 144 reporting an intended sale of 25,578 shares of Common Stock. The shares are described as resulting from restricted stock vesting on 03/16/2026. The filing also discloses prior sales of 48,244 shares on 12/17/2025 for $177,200.21.
The broker of record is Fidelity Brokerage Services LLC at the listed account, and the security is traded on NASDAQ. The filing lists the proposed sale notice date as 03/17/2026.
Esperion Therapeutics Chief Legal Officer Benjamin Looker reported receiving new equity compensation. He was granted a stock option for 269,230 shares of Common Stock at an exercise price of $2.44 per share, expiring on March 13, 2036.
He also received 300,840 shares of Common Stock as a direct grant, bringing his direct Common Stock holdings to 685,056 shares after the award. The stock option award will vest over four years in equal quarterly installments, starting on June 15, 2026.
Esperion Therapeutics, Inc. reported that President and CEO Sheldon L. Koenig received new equity awards. He was granted a stock option covering 647,460 shares of common stock at an exercise price of $2.44 per share, expiring on March 13, 2036, along with 723,760 shares of common stock as a separate award, both at no cash cost to him.
The filing notes that this award will vest over a four-year period in equal quarterly installments beginning on June 15, 2026 Following these grants, Koenig directly holds 2,198,277 shares of Esperion common stock, which includes 3,930 shares recently acquired through Esperion's Employee Stock Purchase Plan.
Esperion Therapeutics Chief Financial Officer Benjamin Halladay reported equity awards. He received a grant of 221,270 stock options to buy Common Stock at an exercise price of $2.44 per share, expiring on March 13, 2036. He was also granted 247,430 shares of Common Stock, bringing his direct holdings to 720,026 shares. The option award will vest over four years in equal quarterly installments, starting on June 15, 2026. Halladay’s reported holdings include 5,071 shares recently acquired through Esperion’s Employee Stock Purchase Plan.
Esperion Therapeutics reports its 2025 annual results and outlines growth plans driven by its bempedoic acid franchise. The company markets oral, once-daily, non-statin LDL-C and cardiovascular risk–lowering drugs NEXLETOL and NEXLIZET in the U.S. and, with partners, NILEMDO and NUSTENDI in Europe and other territories.
In 2025, Esperion generated $159.6 million in net product sales of NEXLETOL and NEXLIZET and $243.6 million in collaboration revenue, up from $115.7 million and $216.6 million in 2024 and $78.3 million and $38.0 million in 2023. Growth reflects milestones, royalties and bulk tablet sales to partners including Otsuka, Daiichi Sankyo entities, Neopharm, CSL Seqirus and HLS Therapeutics, alongside U.S. commercialization.
The business depends heavily on the bempedoic acid tablet and the bempedoic acid/ezetimibe combination, supported by positive CLEAR Outcomes data showing LDL-C and major cardiovascular event reductions in statin-intolerant primary and secondary prevention patients. Management is pursuing label expansions, global launches, next-generation ACLY inhibitors and business development to add complementary products while highlighting substantial risks around concentration in two products, reimbursement, capital needs, debt service, manufacturing via third parties and pending acquisitions.
Esperion Therapeutics reported strong fourth-quarter and full-year 2025 results, driven by its bempedoic acid cardiovascular franchise and partner revenues. Q4 2025 total revenue reached $168.4 million, up 144% year over year, producing net income of $61.8 million and basic EPS of $0.26.
For full-year 2025, total revenue grew 21% to $403.1 million, with U.S. net product revenue up about 38% to $159.6 million and collaboration revenue rising to $243.6 million, though the company still posted a $22.7 million net loss. Cash and cash equivalents increased to $167.9 million.
Esperion outlined a global growth strategy, highlighted a planned acquisition of Corstasis Therapeutics and its Enbumyst nasal spray for edema, and advanced its ACLY-focused pipeline with ESP-2001 for primary sclerosing cholangitis. It expects 2026 operating expenses of $225–$255 million, including about $15 million of stock-based compensation.
Esperion Therapeutics has entered a definitive agreement to acquire Corstasis Therapeutics, maker of Enbumyst, a bumetanide nasal spray approved to treat edema in adults with congestive heart failure and certain liver and kidney diseases. Corstasis will become a wholly owned subsidiary after the merger closes, subject to customary conditions and a potential termination if not completed by May 1, 2026.
Esperion will pay an upfront cash purchase price of $75 million, plus up to $180 million in additional regulatory and commercial milestone payments and low double‑digit royalties on worldwide Enbumyst sales and follow‑on products. Esperion plans to finance the deal through existing credit facilities and monetization of Japanese royalties with Athyrium Capital Management and HealthCare Royalty. The company highlights Enbumyst as a strategic fit with its cardiovascular franchise and expects the transaction to support sustained double‑digit revenue growth and expand its presence across cardiometabolic, hepatic, and renal diseases.
Esperion Therapeutics General Counsel Benjamin Looker reported a small sale of company stock. On 01/20/2026, he sold 1,689 shares of Esperion Therapeutics common stock at a price of $2.882 per share. According to the filing, the shares were sold to satisfy tax obligations arising from vested restricted stock units, meaning the transaction was linked to covering taxes rather than a discretionary open-market sale. Following this transaction, he beneficially owned 384,216 shares directly.
Esperion Therapeutics insider plans a small Rule 144 stock sale. A person named Benjamin Looker filed notice to sell 1,689 shares of common stock of Esperion through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $4,867.02 and 239,063,437 common shares outstanding. The shares to be sold were acquired on 01/15/2026 through restricted stock vesting from the issuer as compensation. Over the prior three months, the same seller disposed of 6,517 common shares on 12/17/2025 for gross proceeds of $23,897.19. By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about Esperion’s operations.
Esperion Therapeutics, Inc. reported preliminary 2025 results and shared expense guidance for the fiscal year ending December 31, 2026. Management currently expects 2026 research and development expenses to range from $40 million to $50 million, selling, general and administrative expenses to range from $170 million to $195 million, and total operating expenses to range from $210 million to $245 million. The figures reflect management’s current expectations and were released in connection with the company’s presentation at the Annual J.P. Morgan Healthcare Conference.